Linked Life Data

18727815

Source:http://linkedlifedata.com/resource/pubmed/id/18727815

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2008-8-27
pubmed:abstractText
Pemphigus vulgaris (PV) is a severe chronic autoimmune blistering disease of skin and mucous membranes. The use of systemic corticosteroids in pemphigus has dramatically reduced its mortality rate, but the long-term use of steroids leads to severe side effects, many of which are serious. For this reason it is often necessary to add immunosuppressive agents to the regimen. However, there are occasional refractory cases in which therapy with conventionally accepted modalities is either not efficacious or not possible on account of side effects. Rituximab is a therapeutic monoclonal antibody targeting CD20, an integral membrane protein highly expressed on the surface of pre-B lymphocytes and activated mature B lymphocytes. We present an instance of refractory PV successfully treated with rituximab. The successful treatment of pemphigus described here demonstrates that rituximab is a viable therapeutic option for patients with refractory PV.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
1529-8019
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
21 Suppl 1
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S6-9
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:18727815-Adult, pubmed-meshheading:18727815-Antibodies, Monoclonal, pubmed-meshheading:18727815-Antibodies, Monoclonal, Murine-Derived, pubmed-meshheading:18727815-Antigens, CD19, pubmed-meshheading:18727815-Antigens, CD20, pubmed-meshheading:18727815-B-Lymphocyte Subsets, pubmed-meshheading:18727815-Drug Administration Schedule, pubmed-meshheading:18727815-Drug Resistance, pubmed-meshheading:18727815-Drug Therapy, Combination, pubmed-meshheading:18727815-Female, pubmed-meshheading:18727815-Humans, pubmed-meshheading:18727815-Immunologic Factors, pubmed-meshheading:18727815-Immunosuppressive Agents, pubmed-meshheading:18727815-Infusions, Intravenous, pubmed-meshheading:18727815-Pemphigus, pubmed-meshheading:18727815-Prednisone, pubmed-meshheading:18727815-Remission Induction
pubmed:year
2008
pubmed:articleTitle
Rituximab in refractory pemphigus vulgaris.
pubmed:affiliation
Department of Dermatology, University of Palermo, Palermo, Italy.
pubmed:publicationType
Journal Article, Case Reports